The dataset used in this research was retrieved specifically for this study from the Chinese National HIV/AIDS Comprehensive Response Information Management System which contains routine care data from the methadone maintenance treatment program. Data are available upon request from the Institutional Review Board of the National Center of AIDS/STD Control and Prevention (NCAIDS) or the Board of Directors of NCAIDS. Applications should be submitted to Dr. Guodong Mi (<mgd@chinaaids.cn>), the Deputy Director of the Office of Directors, NCAIDS.

Introduction {#sec005}
============

Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including hepatitis, cirrhosis, and hepatocellular carcinoma \[[@pone.0147922.ref001]--[@pone.0147922.ref004]\]. Estimates of the HCV antibody prevalence among the Chinese general population have varied from 0.43% to 2.2%, corresponding to a range of 6 million to 30 million people \[[@pone.0147922.ref005]--[@pone.0147922.ref007]\]. While HCV transmission can occur via a variety of modes, the most common route is injecting drug use \[[@pone.0147922.ref003]\], and HCV is the most common viral infection among injecting drug users (IDU) worldwide\[[@pone.0147922.ref008], [@pone.0147922.ref009]\]. China's drug user (DU) population has been estimated to be as high as 3.5 million, most of whom are opioid users and use drugs by injecting \[[@pone.0147922.ref010]\]. Thus, it is not surprising that HCV antibody prevalence among DU in China is thought to be very high, ranging from 15.6% to 98.7% in different geographical areas \[[@pone.0147922.ref011]\]. Meta-analyses have estimated a national HCV antibody prevalence of 67.0% among IDU and 60.1% among DU in methadone maintenance treatment (MMT) \[[@pone.0147922.ref012], [@pone.0147922.ref013]\].

Although implemented in response to the rapidly growing HIV/AIDS epidemic, China's National MMT Program \[[@pone.0147922.ref014]\] also screens clients for anti-HCV upon enrollment and refers those identified as HCV seropositive to appropriate healthcare facilities. The MMT program started with 8 pilot sites in 2004 and has since rapidly expanded to become the world's largest opioid-substitution treatment network \[[@pone.0147922.ref015]\]. By the end of 2012, there were 756 MMT clinics in China that had served about 380,000 clients cumulatively \[[@pone.0147922.ref016]\]. The numbers of MMT clinics vary from 1 to 71 among provincial-level divisions (defined as provinces, autonomous regions, and municipalities). Counties or districts where there are over 500 registered opioid users must have at least one established MMT clinic.

The national HCV antibody prevalence among Chinese MMT clients has not been previously reported. Given the high transmissibility of HCV among IDU, the overall HCV antibody prevalence among MMT clients is thought to be consistently high nationwide, particularly in provincial-level subdivisions with high rates of injecting drug use. We aim to assess the HCV antibody prevalence, risk factors, and geographical distribution among China's MMT client population. The secondary aim is to assess the proportion of MMT clients who have accessed HCV antibody testing.

Materials and Methods {#sec006}
=====================

Study design and participants {#sec007}
-----------------------------

The study cohort comprised all drug users enrolling in the national MMT program between March 2004 and December 2012. Participants were excluded if they could not be tracked by a unique client identification number (e.g., if the same identification number was incorrectly assigned to multiple clients or if the number contained errors). For clients who had dropped out of MMT and re-entered at a subsequent date, we restricted our analysis to the earliest enrollment record. Current guidelines state that all new clients should be screened for HCV antibody upon enrollment and that HCV-negative clients should be tested once every 12 months. Antibody-based testing is provided to all clients free of charge.

Data collection {#sec008}
---------------

Data from this study were abstracted from the national MMT data system, which is one of eight subsystems of the national unified data collection system, the China National HIV/AIDS Comprehensive Response Information Management System (CRIMS). CRIMS is managed by the National Center for AIDS/STD Control and Prevention (NCAIDS) of the Chinese Center for Disease Control and Prevention (Chinese CDC) and has been described in detail elsewhere \[[@pone.0147922.ref017]\]. In brief, the MMT data system is updated daily with service records from each clinic. Local clinics complete baseline assessments at the initial visit to collect information on demographics, medical history, and drug use behavior. From this database, the following data were collected for clients \>16 years of age for this study: sex, date of birth, ethnicity, education level, marital status, occupation, years of drug use, and injecting and needle sharing history, HIV serostatus, HCV serostatus and test dates.

Statistical Analyses {#sec009}
--------------------

We tabulated estimates of provincial- and national-level HCV antibody prevalence. The primary data analyses were limited to clients \>16 years old who had a HCV test result at baseline, which we defined as within 6 months after entry. A binomial distribution, which was normally approximated, was assumed for 95% confidence intervals (CI) for prevalence estimates. Unadjusted odds ratios (OR) were generated by a logistic regression model for each covariate. A test for trend was used to assess the association between years of past drug use and HCV antibody prevalence. Adjusted odds ratios (AOR) were estimated from a multivariable logistic regression model. Variables with p\<0.01 under univariate regression analysis were included in the multivariable model as potential confounders. All statistical analyses were performed using SAS software (Version, 9.3, SAS Institute Inc.,USA). All reported CIs are 95%, and p-values are two-sided.

Ethical approval {#sec010}
----------------

This study was reviewed and approved by the Institutional Review Board of NCAIDS. As all data included here were collected during the regular administration of China's National MMT Program, and all participants in this program provided informed consent at the time of enrollment, no further study-specific informed consent was sought. Data from participants younger than 16 were only used to calculate provincial- and national-level HCV screening coverage and HCV antibody prevalence and were otherwise excluded.

Results {#sec011}
=======

Study Cohort {#sec012}
------------

The development of the study cohort is presented in [Fig 1](#pone.0147922.g001){ref-type="fig"}. Between March 2004 and December 2012, 379,552 drug users had been enrolled into MMT, and 342,443 MMT clients (90.2%) had received a HCV antibody test at least once. Among these clients, 46,234 (13.5%) were excluded from the primary study analyses because their first HCV test result did not occur within 6 months after entry. The final study cohort was composed of 296,209 participants.

![Development of the study cohort.](pone.0147922.g001){#pone.0147922.g001}

### HCV antibody prevalence at baseline {#sec013}

In the initial year of the MMT program in 2004, only 1,438 clients were enrolled. The number of clients enrolled quadrupled in the second year and again in the third year. The peak of newly enrolled clients was 76,528 individuals in 2008, which then decreased from 66,871 in 2009 and to 40,596 in 2012 ([Table 1](#pone.0147922.t001){ref-type="table"}). The proportion of self-reported IDU was stable at 81% in the first three years (2004--2006), but decreased to 76.1% in 2007 and reached a low of 56.0% in 2012. The proportion of clients who obtained HCV testing was less than one-third in 2004 (30.4%) and 2005 (27.8%) and then increased from 59.1% in 2006 and to 93.1% in 2012. The HCV antibody prevalence among overall clients enrolled in 2004 was 34.6%. The HCV antibody prevalence sharply increased to 66.8% in the second year of 2005 but has shown steady annual declines up to the last year of the study in 2012 (45.9%). The HCV antibody prevalence among self-reported IDU peaked at 74.1% in the second year and was stable from 2006--2011 at 70--74% before falling slightly to 68.9% in 2012.

10.1371/journal.pone.0147922.t001

###### Self-reported injecting drug use (IDU), HCV antibody testing, and HCV antibody prevalence among newly enrolled MMT clients by year, 2004--2012.

![](pone.0147922.t001){#pone.0147922.t001g}

                                                                                                             2004                2005                2006                2007                2008                2009                2010                2011                2012                Total
  ---------------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Clients newly enrolled into MMT                                                                            1438                5440                28747               58783               76528               66871               52521               48628               40596               379552
  Self-reported IDU (%)                                                                                      81.2                81.1                81.6                76.1                72.3                66.6                60.6                59.3                56.0                67.7
  HCV testing within 6 months after enrollment (%)                                                           30.4                27.8                59.1                68.7                75.8                79.4                83.6                90.7                93.1                78.0
  Baseline HCV antibody prevalence % (95% CI)                                                                34.6 (30.1--39.0)   66.8 (64.4--69.2)   64.8 (64.1--65.5)   61.7 (61.2--62.2)   59.5 (59.1--59.9)   54.9 (54.5--55.3)   49.9 (49.4--50.3)   49.2 (48.8--49.7)   45.9 (45.4--46.4)   54.6 (54.4--54.8)
  HCV antibody prevalence among clients self-reporting IDU[\*](#t001fn002){ref-type="table-fn"} % (95% CI)   37.4 (32.6--42.3)   74.1 (71.7--76.5)   72.6 (71.9--73.4)   72.9 (72.4--73.4)   73.2 (72.8--73.6)   71.9 (71.4--72.4)   70.5 (69.9--71.0)   70.9 (70.3--71.4)   68.9 (68.3--69.5)   71.7 (71.5--71.9)

CI: confidence interval

\*Among clients with baseline HCV antibody test results.

Geographical Distribution {#sec014}
-------------------------

The utilization of MMT and the HCV antibody prevalence varied significantly by provincial-level division ([Table 2](#pone.0147922.t002){ref-type="table"}). Five provincial-level divisions had more than 30,000 MMT clients, and three had less than 1,000. Eight divisions had more than 10,000 HCV antibody-positive MMT clients.

10.1371/journal.pone.0147922.t002

###### Self-reported injecting drug use (IDU), HCV antibody testing, and HCV antibody prevalence among newly enrolled MMT clients by provincial-level division, 2004--2012.

![](pone.0147922.t002){#pone.0147922.t002g}

  Division                                            Number of MMT clients   Self-reported IDU (%)   Received anti-HCV test at least once (%)[^†^](#t002fn002){ref-type="table-fn"}   HCV seropositivity (%)[^‡^](#t002fn003){ref-type="table-fn"}
  --------------------------------------------------- ----------------------- ----------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------
  Anhui                                               3494                    2603 (74.5)             3281 (93.9)                                                                      1746 (56.6)
  Beijing                                             3264                    2578 (79.0)             3065 (93.9)                                                                      1695 (63.4)
  Chongqing                                           21894                   18940 (86.5)            21016 (96.0)                                                                     14166 (74.5)
  Fujian                                              8179                    5670 (69.3)             7657 (93.6)                                                                      3773 (52.4)
  Gansu                                               16178                   3122 (19.3)             15433 (95.4)                                                                     2176 (15.3)
  Guangdong                                           28656                   23839 (83.2)            25705 (89.7)                                                                     16535 (69.5)
  Guangxi                                             31013                   25405 (81.9)            29060 (93.7)                                                                     18174 (68.9)
  Guizhou                                             37514                   18703 (49.9)            32846 (87.5)                                                                     12257 (45.7)
  Hainan                                              13557                   8754 (70.3)             11175 (82.4)                                                                     3883 (40.4)
  Hebei                                               378                     343 (90.7)              369 (97.6)                                                                       269 (73.9)
  Heilongjiang[\*](#t002fn001){ref-type="table-fn"}   \-                      \-                      \-                                                                               \-
  Henan                                               6209                    891 (14.4)              5888 (94.8)                                                                      403 (7.2)
  Hubei                                               21725                   17493 (80.6)            19835 (91.3)                                                                     11588 (68.3)
  Hunan                                               31205                   24109 (77.3)            27897 (89.4)                                                                     15140 (60.2)
  Inner Mongolia                                      4146                    1934 (46.6)             3954 (95.4)                                                                      1241 (32.5)
  Jiangsu                                             8764                    7440 (84.9)             8546 (97.5)                                                                      5851 (71.7)
  Jiangxi                                             5119                    4458 (87.1)             4559 (89.1)                                                                      2692 (69.2)
  Jilin                                               323                     306 (94.7)              275 (85.1)                                                                       141 (65.0)
  Liaoning[\*](#t002fn001){ref-type="table-fn"}       \-                      \-                      \-                                                                               \-
  Ningxia                                             5012                    1822 (36.4)             4543 (90.6)                                                                      1038 (26.4)
  Qinghai                                             1266                    846 (66.8)              1225 (96.8)                                                                      783 (67.5)
  Shandong                                            67                      59 (88.1)               36 (53.7)                                                                        21 (72.4)
  Shanghai                                            6188                    4722 (76.3)             5365 (86.7)                                                                      2966 (66.4)
  Shannxi                                             21171                   13140 (62.1)            19391 (91.6)                                                                     8555 (50.0)
  Shanxi                                              4583                    365 (8.0)               4103 (89.5)                                                                      212 (5.6)
  Sichuan                                             34839                   23434 (67.3)            29610 (85.0)                                                                     11227 (50.2)
  Tianjin                                             1411                    1308 (92.7)             1389 (98.4)                                                                      1072 (78.1)
  Tibet[\*](#t002fn001){ref-type="table-fn"}          \-                      \-                      \-                                                                               \-
  Xinjiang                                            13104                   11181 (85.3)            11886 (90.7)                                                                     7019 (68.5)
  Yunnan                                              35427                   23663 (66.8)            31167 (88.0)                                                                     12541 (54.3)
  Zhejiang                                            14866                   7853 (52.8)             13168 (88.6)                                                                     4523 (38.7)
  **Total**                                           **379595**              **254981 (67.7)**       **342443 (90.2)**                                                                **161687 (54.6)**

\*Division did not have an MMT clinic by the end of 2012.

^†^ Based on MMT clients who received at least one HCV antibody test (baseline or follow-up test).

^‡^Based on MMT clients with baseline HCV antibody test results.

The baseline HCV antibody prevalence ranged from a low of 5.6% in Shanxi province to a high of 78.1% in Tianjin municipality. The distributions of HCV antibody prevalence and proportion of self-reported IDU nationwide are presented in [Fig 2](#pone.0147922.g002){ref-type="fig"}. Data were not available from some provincial-level divisions because the MMT program has not yet been established in those areas.

![The geographical distribution of (A) HCV antibody prevalence and (B) proportion of injecting drug use among MMT clients with baseline HCV test results in China.](pone.0147922.g002){#pone.0147922.g002}

The demographic and drug use characteristics of the cohort are summarized in [Table 3](#pone.0147922.t003){ref-type="table"}. The overall HCV antibody prevalence upon entry among the 296,209 MMT clients with baseline test results was 54.6% (95% CI: 54.5--54.8). Most clients were male (84.9%), middle-aged (30--44 years 64.6%), Han Chinese (85.7%), educated beyond middle school (79.2%), unmarried (52.3%), and unemployed (66.3%). The HIV antibody prevalence was 5.8%. More than half (51.1%) reported having used drugs for 9 or more years prior to enrollment in MMT. While two-thirds of clients self-reported drug use through injecting (66.8%), most reported that they had never shared needles (87.6%). HCV antibody prevalence was highest among HIV-positive clients (79.7%, 95% CI: 79.1--80.3) and those who had reported injecting drugs (71.7%, 95% CI: 71.5--71.9) or sharing needles (78.5%, 95% CI: 78.1--78.9).

10.1371/journal.pone.0147922.t003

###### HCV antibody prevalence and risk factors among MMT clients with baseline HCV test results in China, 2004--2012.

![](pone.0147922.t003){#pone.0147922.t003g}

                                           Participants, N (%)   HCV Cases, n   Prevalence, % (95% CI)   Unadjusted OR, (95% CI)   P-value    Adjusted OR, (95% CI)   P-value
  ---------------------------------------- --------------------- -------------- ------------------------ ------------------------- ---------- ----------------------- ----------
  ***Demographic characteristics***                                                                                                                                   
  **Gender**                                                                                                                                                          
   Male                                    251599 (84.9)         135395         53.8 (53.6--54.0)        1.0                                  1.0                     
   Female                                  44610 (15.1)          26292          58.9 (58.5--59.4)        1.23 (1.21--1.26)         \<0.0001   1.39 (1.36--1.43)       \<0.0001
  **Age (years)**                                                                                                                                                     
   16--29                                  71881 (24.3)          35664          49.6 (49.2--50.0)        1.00                                 1.00                    
   30--44                                  191480 (64.6)         109550         57.2 (57.0--57.4)        1.36 (1.34--1.38)         \<0.0001   1.35 (1.31--1.38)       \<0.0001
   ≥45                                     32848 (11.1)          16473          50.1 (49.6--50.7)        1.02 (1.00--1.05)         \<0.0001   1.28 (1.24--1.33)       \<0.0001
  **Ethnicity**                                                                                                                                                       
   Han                                     253947 (85.7)         140492         55.3 (55.1--55.5)        1.00                                 1.00                    
   Hui                                     7529 (2.5)            3089           41.0 (39.9--42.1)        0.56 (0.54--0.59)         \<0.0001   0.77 (0.73--0.82)       \<0.0001
   Uyghur                                  7086 (2.4)            4900           69.1 (68.1--70.2)        1.81 (1.72--1.90)         \<0.0001   1.34 (1.26--1.42)       \<0.0001
   Zhuang                                  8976 (3.0)            5435           60.6 (59.5--61.6)        1.24 (1.19--1.29)         \<0.0001   1.29 (1.22--1.36)       \<0.0001
   Other                                   18631 (6.3)           7745           41.6 (40.9--42.3)        0.58 (0.56--0.59)         \<0.0001   0.78 (0.75--0.81)       \<0.0001
   Missing data                            40 (0)                26                                                                                                   
  **Education level**                                                                                                                                                 
   ≤ Primary school                        61629 (20.8)          32446          52.6 (52.3--53.0)        1.00                                 1.00                    
   Middle school                           170559 (57.6)         94927          55.7 (55.4--55.9)        1.13 (1.11--1.15)         \<0.0001   1.02 (1.00--1.05)       \<0.0001
   ≥ High school                           63993 (21.6)          34294          53.6 (53.2--54.0)        1.04 (1.02--1.06)         0.0146     0.95 (0.92--0.98)       \<0.0001
   Missing data                            28 (0)                8                                                                                                    
  **Marital Status**                                                                                                                                                  
   Married                                 140732 (47.5)         67830          48.2 (47.9--48.5)        1.00                                 1.00                    
   Unmarried                               155009 (52.3)         93600          60.4 (60.1--60.6)        1.64 (1.61--1.66)         \<0.0001   1.25 (1.23--1.28)       \<0.0001
   Missing data                            468 (0.2)             257                                                                                                  
  **Occupation**                                                                                                                                                      
   Employed                                99927 (33.7)          47516          47.6 (47.2--47.9)        1.00                                 1.00                    
   Unemployed                              196252 (66.3)         114150         58.2 (58.0--58.4)        1.53 (1.51--1.56)         \<0.0001   1.12 (1.11--1.15)       \<0.0001
   Missing data                            30 (0)                21                                                                                                   
  **HIV serostatus**                                                                                                                                                  
   Negative                                254170 (85.8)         133180         52.4 (52.2--52.6)        1.00                                 1.00                    
   Positive                                17200 (5.8)           13700          79.7 (79.1--80.3)        3.56 (3.42--3.70)         \<0.0001   1.74 (1.67--1.82)       \<0.0001
   Missing data                            24839 (8.4)           14806                                                                                                
  ***Drug use history characteristics***                                                                                                                              
  **Duration (years)**                                                                                                                                                
   0--2                                    55874 (18.9)          18611          33.3 (32.9--33.7)        1.00                                 1.00                    
   3--5                                    44525 (15.0)          20812          46.7 (46.3--47.2)        1.76 (1.71--1.80)         \<0.0001   1.31 (1.27--1.35)       \<0.0001
   6--8                                    43063 (14.5)          24801          57.6 (57.1--58.1)        2.72 (2.65--2.79)         \<0.0001   1.67 (1.62--1.72)       \<0.0001
   ≥ 9                                     151408 (51.1)         96823          63.9 (63.7--64.2)        3.55 (3.48--3.63)         \<0.0001   2.01 (1.96--2.06)       \<0.0001
   Missing data                            1339 (0.5)            640            47.8 (45.1--50.5)                                                                     
  **Injecting drug use**                                                                                                                                              
   No                                      96824 (32.7)          19333          20.0 (19.7--20.2)        1.00                                 1.00                    
   Yes                                     197832 (66.8)         141810         71.7 (71.5--71.9)        10.15 (9.96--10.34)       \<0.0001   8.34 (8.17--8.52)       \<0.0001
   Missing data                            1553 (0.5)            544                                                                                                  
  **Ever shared needles**                                                                                                                                             
   No                                      259459 (87.6)         132830         51.2 (51.0--51.4)        1.00                                 1.00                    
   Yes                                     36747 (12.4)          28854          78.5 (78.1--78.9)        3.49 (3.40--3.58)         \<0.0001   1.52 (1.48--1.57)       \<0.0001
   Missing data                            3 (0)                 3                                                                                                    
   Total                                   296209                161687         54.6 (54.5--54.8)                                                                     

CI: confidence interval, OR: odds ratio.

Risk factors associated with HCV infection {#sec015}
------------------------------------------

Risk factors associated with being HCV antibody positive are shown in [Table 3](#pone.0147922.t003){ref-type="table"}. The risk was higher for participants who were female (AOR: 1.39, 95% CI: 1.36--1.43, p\<0.0001), over 30 years (30--44 years AOR: 1.35, 95% CI: 1.31--1.38, p\<0.0001; age group ≥45 years AOR: 1.28, 95% CI: 1.24--1.33, p\<0.0001), of Uyghur or Zhuang ethnicity (Uyghur AOR: 1.34, 95% CI: 1.29--1.42, p\<0.0001; Zhuang AOR: 1.29, 95% CI: 1.22--1.36, p\<0.0001), having attained a middle school education (AOR: 1.02, 95% CI: 1.00--1.05, p\<0.0001 compared to primary school), unmarried (AOR: 1.25, 95% CI: 1.23--1.28, p\<0.0001), unemployed (AOR: 1.12, 95% CI: 1.11--1.15, p\<0.0001), HIV-positive (AOR: 1.74, 95% CI: 1.67--1.82, p\<0.0001), had a longer history of drug use (≥9 years AOR: 2.01, 95% CI: 1.96--2.06; 6--8 years AOR: 1.67, 95% CI: 1.62--1.72; 3--5 years AOR: 1.31, 95% CI:1.27--1.35, all p\<0.0001and trend test p\<0.0001), had reported injecting drug use (AOR: 8.34, 95% CI: 8.17--8.52, p\<0.0001) and had ever shared needles (AOR: 1.52, 95% CI: 1.48--1.57, p\<0.0001).

Discussion {#sec016}
==========

China's national MMT program was established as part of an overarching strategy to stem the HIV epidemic. The national MMT program provides regular anti-HCV testing, and the HCV antibody prevalence has not been previously described. Although the HIV epidemic is largely concentrated in six provincial-level divisions, HCV antibody prevalence among MMT clients was presumed to be high nationwide due to its high transmissibility, particularly through injecting drug use. By utilizing the National MMT Program database, we presented an overview of the prevalence, risk factors, and geographical distribution of anti-HCV seropositivity in the Chinese MMT client population from the program's inception in 2004 through 2012.

The primary strength of this observational study is the large sample size and access to the National MMT program database, which covers nearly all geographical regions in China. The length of the study period covers the entire existence of the Chinese MMT program from 2004 to 2012, which allows for monitoring of HCV antibody prevalence trends among newly enrolled MMT clients. Due to the large sample size and high coverage of areas, the results of this study allow for a comprehensive assessment of HCV epidemiology among DUs in China.

HCV antibody prevalence {#sec017}
-----------------------

From 2004 to 2012, the overall HCV antibody prevalence for all MMT clients at enrollment was 54.6%. This is lower than the prevalence estimates from recent meta-analyses of 67.0% among IDUs and 60.1% among DUs in MMT \[[@pone.0147922.ref012], [@pone.0147922.ref013]\]. Drug injecting was reported by 66.8% of clients, and 12.4% reported needle sharing. The HCV antibody prevalence among IDUs in MMT in our cohort was higher (71.7%) than previous estimates of 61.4% and 66.97%, although it is worth noting that their studies focused on IDUs regardless of MMT enrollment \[[@pone.0147922.ref018], [@pone.0147922.ref019]\].

The HCV antibody prevalence in the Chinese MMT program is similar to estimates reported in MMT clinics in other countries. Most studies of HCV antibody prevalence among MMT clients in other countries (including the United States, Switzerland, and Australia) were limited to individual cities or MMT clinics \[[@pone.0147922.ref020]--[@pone.0147922.ref024]\]. These studies showed variance in HCV antibody prevalence among MMT clients ranging from 58% to 87%. Direct comparisons between sites and studies are unreliable due to the differences in study cohort profiles, particularly related to the percentages of IDU and non-injecting DU.

In China, the HCV antibody prevalence of clients upon MMT entry has declined each year from 2005 (66.8%) to 2012 (45.9%). (An exception is the first year of the MMT program in 2004, which reported a rate of 34.6%; this may be due to the very low HCV antibody screening coverage and unreliable lab results during the initial pilot period of the MMT program). It may be that the decreasing annual HCV antibody prevalence results is driven by the decreasing proportions of IDUs among newly enrolled MMT clients. Concurrently, the HCV antibody testing coverage at baseline has greatly increased from 30.4% in 2004 to 93.1% in 2012, which indicates a remarkable improvement in MMT health services and linkage to anti-HCV testing.

Risk Factors {#sec018}
------------

The factors most strongly associated with HCV infection were related to drug use history, which has been addressed in depth in the literature. The prevalence of HCV increased with longer histories of drug use \[[@pone.0147922.ref003], [@pone.0147922.ref025]--[@pone.0147922.ref027]\]. HCV infection was also much more likely to be present among IDUs and HIV-positive clients \[[@pone.0147922.ref003], [@pone.0147922.ref008], [@pone.0147922.ref019], [@pone.0147922.ref026]\].

One factor that has not been addressed thoroughly is the difference in anti-HCV prevalence by sex. Women had a higher prevalence of 58.9% compared to a prevalence of 53.8% for men. Other studies on HCV antibody and DU in China in the English and Chinese research literature were not at a consensus on sex as a risk factor \[[@pone.0147922.ref011], [@pone.0147922.ref018], [@pone.0147922.ref026]--[@pone.0147922.ref029]\]. In the national general population, there is no significant difference in HCV antibody prevalence between sex \[[@pone.0147922.ref030]\]. However, another study also suggests that sexual transmission of HCV may be more efficient in females \[[@pone.0147922.ref024]\]. Future research should address sex as a risk factor for HCV antibody positivity.

Geographical Distribution {#sec019}
-------------------------

Our findings indicate that the HCV antibody prevalence among MMT clients is alarmingly high throughout China. Of the 28 provincial-level divisions included in our study, 20 reported rates above 50%, including 5 divisions with prevalence above 70%. HCV antibody prevalence showed extremely wide variations between divisions. We believe that these differences can be attributed in part to the different distribution of IDU in regions. In the provincial-level divisions with the two lowest HCV antibody prevalence, Henan and Shanxi, we found that these two provinces had very low percentages of clients who reported having injected drugs (Henan: 14.0%; Shanxi: 8.1%) compared to the national percentage (66.8%). Tianjin, the provincial-level division with highest rate of HCV antibody prevalence at 78.1%, also had a remarkably high percentage of IDUs (92.7%). Regions with high proportions of IDUs should be focal regions for controlling the HCV epidemic. Of all provincial-level divisions that have implemented MMT, eight had more than 10,000 HCV antibody positive MMT clients.

Comparison to the HIV Epidemic {#sec020}
------------------------------

The Chinese MMT program was originally implemented as a response to the emerging HIV epidemic\[[@pone.0147922.ref014]\]. Historically and presently, the HIV epidemic in China has been largely concentrated in 6 provincial-level divisions: Yunnan, Guangxi, Henan, Sichuan, Xinjiang and Guangdong \[[@pone.0147922.ref031]\]. With the exception of Henan, these divisions lie along major drug trafficking routes and are the top five are as for HCV and HIV co-infection. While MMT has contributed to slowing the spread of HIV, MMT without other harm reduction strategies has not been as effective for controlling the HCV epidemic \[[@pone.0147922.ref032]\]. This situation is not unique to China; studies from many countries have noted that HCV has a higher transmission probability than HIV \[[@pone.0147922.ref025], [@pone.0147922.ref033], [@pone.0147922.ref034]\]. One example is Hong Kong, where under a long-established MMT program with over 90% coverage, HIV antibody prevalence was 0.3% and HCV antibody prevalence was 85% \[[@pone.0147922.ref023]\].

Recommendations {#sec021}
---------------

Because many IDUs first begin drug use through non-injecting methods \[[@pone.0147922.ref035]\], implementing outreach efforts to this population of non-injecting DUs can potentially prevent transition to drug injecting \[[@pone.0147922.ref033]\]. Data showed a 71.7% HCV antibody prevalence for IDUs compared to 20.0% for non-injecting DUs. This HCV antibody prevalence for non-injecting DUs is comparable to other studies reporting rates of 2.3% to 35.3% \[[@pone.0147922.ref019], [@pone.0147922.ref036]\], and the difference in prevalence between IDUs and non-injecting DUs is similar to results from other studies \[[@pone.0147922.ref019], [@pone.0147922.ref033]\]. In our data, the low proportion of IDU in Henan and Shanxi is strongly correlated with the remarkably low HCV antibody prevalence in these two provinces. We recommend further investigation on what distinguishes these two provinces in this regard from the rest of the country.

Emphasizing routine testing for HCV antibody is critically important for MMT clients because a positive serostatus has clinical implications. Low levels of HCV knowledge has been cited as a barrier to antibody testing and treatment in China and abroad \[[@pone.0147922.ref037], [@pone.0147922.ref038]\]. Clients who were positive for HCV antibody have been shown to need significantly higher dosages of methadone \[[@pone.0147922.ref024]\]. Researchers have recommended that it would be beneficial for anti-HCV positive clients to receive treatment of HCV infection at methadone clinics\[[@pone.0147922.ref039]\], echoing a similar suggestion regarding antiretroviral therapy for HIV. Cost is a significant barrier to clients because unlike ART, neither methadone nor HCV treatment is free in China. MMT services costs up to 10 RMB per day (\~\$1.60 USD).

Finally, we recommend further expansion of China's needle and syringe exchange programs to supplement MMT. Multi-component harm reduction strategies that include MMT and needle and syringe exchange programs have shown effectiveness is reducing the risk of HCV seroconversion up to 75--80% \[[@pone.0147922.ref032], [@pone.0147922.ref040]\]. In 2011, China had 913 needle and syringe exchange sites, which distributed 12 million needles and syringes to over 60,000 IDUs \[[@pone.0147922.ref016]\]. However, it is estimated that only about 2% of IDUs in China have been able to access needle exchange programs so far \[[@pone.0147922.ref041]\].

Limitations {#sec022}
-----------

While our study relied on HCV antibody tests to determine infection status, it is notable that spontaneous resolution or viral clearance occurs in 15--20% of individuals, which varies by race and sex \[[@pone.0147922.ref042], [@pone.0147922.ref043]\]. Our study is limited to describing HCV antibody prevalence, instead of clinical presentation of active HCV. We were also limited to describing the HCV antibody prevalence upon entry to MMT, which is not directly reflective of all MMT clients. We could only include MMT clients who had at least one anti-HCV test result within 6 months in the primary analysis; due to the high early attrition rate in MMT, many clients drop-out without receiving HCV antibody testing \[[@pone.0147922.ref044], [@pone.0147922.ref045]\]. We excluded 13.5% of cases due to a lack of HCV antibody testing within 6 months of entry. Most excluded participants had enrolled in MMT at early stages of the program when anti-HCV testing rates were comparatively low. Compared with MMT clients without baseline HCV test results, MMT clients with a known baseline serostatus have a slightly lower proportion of self-reported IDU and needle sharing, and have a longer history of drug use. Also, some clients may acquire HCV during the course of MMT due to ongoing drug use \[[@pone.0147922.ref046]\]. As these four factors increase the risk for HCV infection, the HCV antibody prevalence of all MMT clients may be slightly higher than the prevalence among MMT clients who were tested at entry. However, we believe that these differences would not have a large impact on the final results nor would it alter our conclusions. We also acknowledge that the accuracy and reliability of data is dependent on the performance of local staff from clinics located around the country, including in resource-limited areas. Due to the different brands of anti-HCV tests, this may also have caused slight variations between different MMT clinics. We attempted to reduce the role of confounding variables by using a multivariable analysis model but as in all observational studies, there still remains a residual risk of confounding. Finally, due to the extremely large number of cases included in the analysis, we acknowledge that a relatively slight difference between groups can create a statistically significant estimate.

Our study concludes that the HCV antibody prevalence among MMT clients has reached alarmingly high rates in many areas within China, which is reflective of the high transmissibility of HCV. Routine antibody screening, treatment options that address drug use, HCV infection, and potential HIV/HCV co-infection, and continued expansion of MMT and needle and syringe exchange programs are critical components of a comprehensive national control and prevention strategy.
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